Sunday 22 December 2024

The Pharma Letter Podcast — Episode 14 — A vaccine for Alzheimer's?

Biotechnology
Simon Wentworth
6 June 2022
episode14-big


More on this story...

Biotechnology
Encouraging early results in Alzheimer's for Prothena
26 July 2021
Biotechnology
Prothena pens $1.2 billion deal with Novo Nordisk
12 July 2021
Biotechnology
Roche and Prothena move forward with PD drug prasinezumab
22 October 2020
Biotechnology
Roche's 10-year Alzheimer's study yields depressingly familiar result
16 June 2022


Companies featured in this story

More ones to watch >


Today's issue

The week in pharma: action, reaction and insight – week to December 20
Pharmaceutical
The week in pharma: action, reaction and insight – week to December 20
22 December 2024
Biotechnology
FDA approves Novo Nordisk’s Alhemo
22 December 2024
Pharmaceutical
Italfarmaco’s Duvyzat backed by MHRA
22 December 2024
Pharmaceutical
Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Biotechnology
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Biotechnology
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Biotechnology
Regeneron advances anticoagulant antibody program
20 December 2024

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.




More Features in Biotechnology

FDA approves Novo Nordisk’s Alhemo
22 December 2024
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Regeneron advances anticoagulant antibody program
20 December 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze